Chapter/Section Purchase

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CT-2009
1.2.3 POL-6014
1.2.4 ARO-AAT
1.2.5 ALNAAT-02
1.2.6 Others
1.3 Market by Application
1.3.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Perspective (2017-2028)
2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Region
2.2.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Region (2017-2022)
2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028)
2.3 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
2.3.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
2.3.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
2.3.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
2.3.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue
3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2017-2022)
3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
3.4 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio
3.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2021
3.5 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.6 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
3.7 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Type
4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2017-2022)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2023-2028)
5 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Application
5.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Application (2017-2022)
5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2017-2028)
6.2 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type
6.2.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2022)
6.2.2 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2023-2028)
6.2.3 North America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application
6.3.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2022)
6.3.2 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2023-2028)
6.3.3 North America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country
6.4.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
6.4.2 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2017-2028)
7.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type
7.2.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2022)
7.2.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2023-2028)
7.2.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application
7.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2022)
7.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2023-2028)
7.3.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country
7.4.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
7.4.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size (2017-2028)
8.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Type
8.2.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Application
8.3.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region
8.4.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size (2017-2028)
9.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Type
9.2.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
9.3 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Application
9.3.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
9.4 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country
9.4.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size (2017-2028)
10.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Type
10.2.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Application
10.3.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country
10.4.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Adverum Biotechnologies, Inc.
11.1.1 Adverum Biotechnologies, Inc. Company Details
11.1.2 Adverum Biotechnologies, Inc. Business Overview
11.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.1.5 Adverum Biotechnologies, Inc. Recent Developments
11.2 Alnylam Pharmaceuticals, Inc.
11.2.1 Alnylam Pharmaceuticals, Inc. Company Details
11.2.2 Alnylam Pharmaceuticals, Inc. Business Overview
11.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.2.5 Alnylam Pharmaceuticals, Inc. Recent Developments
11.3 Applied Genetic Technologies Corporation
11.3.1 Applied Genetic Technologies Corporation Company Details
11.3.2 Applied Genetic Technologies Corporation Business Overview
11.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
11.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.3.5 Applied Genetic Technologies Corporation Recent Developments
11.4 Arrowhead Pharmaceuticals, Inc.
11.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
11.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview
11.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
11.5 Carolus Therapeutics, Inc.
11.5.1 Carolus Therapeutics, Inc. Company Details
11.5.2 Carolus Therapeutics, Inc. Business Overview
11.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.5.5 Carolus Therapeutics, Inc. Recent Developments
11.6 Cevec Pharmaceuticals GmbH
11.6.1 Cevec Pharmaceuticals GmbH Company Details
11.6.2 Cevec Pharmaceuticals GmbH Business Overview
11.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
11.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.6.5 Cevec Pharmaceuticals GmbH Recent Developments
11.7 Dicerna Pharmaceuticals, Inc.
11.7.1 Dicerna Pharmaceuticals, Inc. Company Details
11.7.2 Dicerna Pharmaceuticals, Inc. Business Overview
11.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments
11.8 Digna Biotech, S.L.
11.8.1 Digna Biotech, S.L. Company Details
11.8.2 Digna Biotech, S.L. Business Overview
11.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
11.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.8.5 Digna Biotech, S.L. Recent Developments
11.9 Editas Medicine, Inc.
11.9.1 Editas Medicine, Inc. Company Details
11.9.2 Editas Medicine, Inc. Business Overview
11.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.9.5 Editas Medicine, Inc. Recent Developments
11.10 Grifols, S.A.
11.10.1 Grifols, S.A. Company Details
11.10.2 Grifols, S.A. Business Overview
11.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
11.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.10.5 Grifols, S.A. Recent Developments
11.11 Inhibrx
11.11.1 Inhibrx Company Details
11.11.2 Inhibrx Business Overview
11.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
11.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.11.5 Inhibrx Recent Developments
11.12 Intellia Therapeutics, Inc.
11.12.1 Intellia Therapeutics, Inc. Company Details
11.12.2 Intellia Therapeutics, Inc. Business Overview
11.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.12.5 Intellia Therapeutics, Inc. Recent Developments
11.13 International Stem Cell Corporation
11.13.1 International Stem Cell Corporation Company Details
11.13.2 International Stem Cell Corporation Business Overview
11.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
11.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.13.5 International Stem Cell Corporation Recent Developments
11.14 Ionis Pharmaceuticals, Inc.
11.14.1 Ionis Pharmaceuticals, Inc. Company Details
11.14.2 Ionis Pharmaceuticals, Inc. Business Overview
11.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.14.5 Ionis Pharmaceuticals, Inc. Recent Developments
11.15 Kamada Ltd.
11.15.1 Kamada Ltd. Company Details
11.15.2 Kamada Ltd. Business Overview
11.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
11.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.15.5 Kamada Ltd. Recent Developments
11.16 Polyphor Ltd.
11.16.1 Polyphor Ltd. Company Details
11.16.2 Polyphor Ltd. Business Overview
11.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
11.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.16.5 Polyphor Ltd. Recent Developments
11.17 ProMetic Life Sciences Inc.
11.17.1 ProMetic Life Sciences Inc. Company Details
11.17.2 ProMetic Life Sciences Inc. Business Overview
11.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.17.5 ProMetic Life Sciences Inc. Recent Developments
11.18 rEVO Biologics, Inc.
11.18.1 rEVO Biologics, Inc. Company Details
11.18.2 rEVO Biologics, Inc. Business Overview
11.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.18.5 rEVO Biologics, Inc. Recent Developments
11.19 Sangamo BioSciences, Inc.
11.19.1 Sangamo BioSciences, Inc. Company Details
11.19.2 Sangamo BioSciences, Inc. Business Overview
11.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
11.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
11.19.5 Sangamo BioSciences, Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer